Privately-held Circassia Ltd of the UK has raised £60 million to be paid over two years from Imperial Innovations Group Plc and other investors in order to finance the development of its T-cell vaccines to treat a range of allergies. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
